Merck gets US FDA emergency use nod for treatment of screwworm in dogs
The US FDA granted emergency use authorization for Merck's Bravecto tablets to treat New World screwworm in dogs, citing potential effectiveness and public health needs. The drug is already approved for flea and tick treatments but carries neurological side effect risks. The authorization was issued to Intervet, Merck's US animal health unit.
How this was made
The 30-second read
Why it matters
The FDA concluded benefits outweigh risks for authorized use, while reiterating monitoring and neurological side-effect associations typical for the isoxazoline class.
Market read
A direct FDA regulatory action for a specific new veterinary indication is a tradable catalyst for Merck’s animal health segment, though likely constrained by limited outbreak geography.
What to watch
Neurological side-effect associations for isoxazolines could dampen uptake or increase clinician caution, limiting incremental demand despite the new authorization.
Background
Bravecto (fluralaner) is already approved for certain flea- and tick-related uses in dogs and puppies; the FDA EUA expands its use to New World screwworm treatment.
Ticker impact
FDA issued an emergency use authorization for Merck’s Bravecto tablets to treat New World screwworm in dogs, expanding approved use under prescription-only rules.
Likely modest positive bias as traders price in incremental sales and broader treatment access, partially offset by safety-label attention.
The article is a first-time FDA EUA for Bravecto’s new indication, which is a direct regulatory catalyst. However, it is an emergency authorization with limited geographic case scope, so the magnitude is likely moderate rather than transformative.
Market effects
Highlights ongoing regulatory pathways for animal antiparasitics and may increase attention on isoxazoline safety monitoring in veterinary use.
Focuses on dogs in or returning from affected US geographic areas, potentially concentrating near-term demand in those regions.
US EUA could influence how quickly similar treatments are considered or adopted in other markets facing screwworm outbreaks.
Counterpoint
Because the EUA is limited to a restricted geographic area and remains prescription-only, near-term revenue impact may be smaller than bulls expect.
Key entities
- companyMerck
Issuer of Bravecto tablets; subject of the FDA emergency use authorization news.
- productBravecto
Fluralaner antiparasitic tablets authorized under EUA for New World screwworm in dogs and puppies.
- regulatorFDA
Issued the emergency use authorization and outlined monitoring and risk considerations.
- business_unitIntervet
Merck’s US animal health unit named as the EUA recipient.
